HOME >> BIOLOGY >> NEWS
A humble aquarium fish may be the key to new therapies for birth defects

anges that take place in their embryos from the moment of fertilization. The small fish have another advantage for studying the role of nutrition: Scientists can precisely regulate the nutrients that the embryo receives largely free from maternal influence.

In the paper, the researchers describe the discovery of a mutation in the zebrafish that disrupts the distribution of the critical nutrient copper within the fish cells and causes defects that are remarkably similar to those observed in children suffering from Menkes kinky hair disease, which, in its most severe form, causes degeneration and death within two to three years after birth.

"We found this mutation about two and a half years ago," said Solnica-Krezel. "Because it impairs so many aspects of normal development and causes the embryo to fall apart in two days, we named it 'Calamity.'" Six months later, she heard a talk that Gitlin gave at a scientific meeting about the results of exposing zebrafish embryos to a chemical agent that disrupts copper metabolism. She was struck by the similarity between his results and those produced by Calamity, so she approached him and they decided to collaborate.

"Lila and the other zebrafish geneticists have created all these wonderful tools," said Gitlin. "I feel like a cook that walks into this wonderfully equipped kitchen and realizes there all these wonderful recipes that he can prepare!"

The researchers explored the effect on embryo development of varying the amount of copper available and disabling different pieces of the molecular mechanisms that cells use to handle this potentially toxic material. The consequences were quite dramatic because copper-containing enzymes play a number of critical roles in the life of the cell. They are involved in the process by which a cell burns sugars and disposes of the carbon dioxide and water byproducts. They are required to produce pigmentation and develop connective tissue. These "cuproen
'"/>

Contact: David F. Salisbury
david.salisbury@vanderbilt.edu
615-343-6803
Vanderbilt University
8-Aug-2006


Page: 1 2 3 4

Related biology news :

1. Newly discovered fish named after New York aquarium biologist
2. New asthma gene could lead to new therapies
3. Scientists decode RNA mystery, will help aim drug therapies
4. Genomic signatures identify targeted therapies for lung cancer
5. Existence of muscle-building stem cells points to regenerative therapies for muscular disease
6. Antibody-based therapies effective at controlling malaria
7. Preterm infants with RDS -- surfactant replacement therapies improves neonatal survival
8. UBC discovery may lead to smart therapies for breast, ovarian cancer
9. NDDO and ESMO joined by US National Cancer Institute in conferences on targeted cancer therapies
10. U of MN adult stem cell research shows promise for transplant therapies
11. Boost for new cancer therapies

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/16/2016)... 16, 2016 Research and Markets has announced ... Global Forecast to 2021" report to their offering. ... The biometric vehicle access ... a CAGR of 14.06% from 2016 to 2021. The market is ... to reach 854.8 Million by 2021. The growth of the biometric ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
(Date:12/15/2016)...  There is much more to innovative access systems ... Continental will demonstrate the intelligence of today,s solutions at ... Through the combination of the keyless entry and start ... the international technology company is opening up new possibilities ... "The integration of biometric elements brings our expertise ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... and GAITHERSBURG, Md. ... MKT: PIP) and Altimmune, Inc., a privately-held immunotherapeutics ... of a definitive agreement for the merger of ... current investors include Novartis Venture Fund, HealthCap, Truffle ... be a fully-integrated and diversified immunotherapeutics company with ...
(Date:1/19/2017)... AquaBounty Technologies, Inc. (AIM: ABTU; NASDAQ: AQB), ... and a majority-owned subsidiary of Intrexon Corporation (NYSE: ... listing of its common shares on the NASDAQ Stock ... "AquaBounty,s listing on NASDAQ represents an important milestone ... the U.S. markets as we advance plans for commercial ...
(Date:1/19/2017)... Ca (PRWEB) , ... January 18, 2017 , ... ... events for tech innovators, engineers, and scientists from around the world, was today ... News. The awards program is based entirely on merit and decided upon by ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... services spanning the full spectrum of drug and device development, and Prism ... pharma/device companies and clinicians, today announced Verified Clinical Trials (VCT) has ...
Breaking Biology Technology:
Cached News: